One such incretin, glucagon‐like peptide 1 (GLP‐1), forms the basis of the only islet GPCR‐targeted therapy for T2D, and GLP‐1 receptor analogues such as exenatide and liraglutide have been used clinically for over a decade. Here, GLP1R is linked to type 2 diabetes mellitus.